Journal of Clinical Immunology

, Volume 32, Issue 1, pp 39–49 | Cite as

Successful Treatment with Infliximab for Inflammatory Colitis in a Patient with X-linked Anhidrotic Ectodermal Dysplasia with Immunodeficiency

  • Tomoyuki Mizukami
  • Megumi Obara
  • Ryuta Nishikomori
  • Tomoki Kawai
  • Yoshihiro Tahara
  • Naoki Sameshima
  • Kousuke Marutsuka
  • Hiroshi Nakase
  • Nobuhiro Kimura
  • Toshio Heike
  • Hiroyuki NunoiEmail author


X-linked anhidrotic ectodermal dysplasia with immunodeficiency (X-EDA-ID) is caused by hypomorphic mutations in the gene encoding nuclear factor-κB essential modulator protein (NEMO). Patients are susceptibile to diverse pathogens due to insufficient cytokine and frequently show severe chronic colitis. An 11-year-old boy with X-EDA-ID was hospitalized with autoimmune symptoms and severe chronic colitis which had been refractory to immunosuppressive drugs. Since tumor necrosis factor (TNF) α is responsible for the pathogenesis of NEMO colitis according to intestinal NEMO and additional TNFR1 knockout mice studies, and high levels of TNFα-producing mononuclear cells were detected in the patient due to the unexpected gene reversion mosaicism of NEMO, an anti-TNFα monoclonal antibody was administered to ameliorate his abdominal symptoms. Repeated administrations improved his colonoscopic findings as well as his dry skin along with a reduction of TNFα-expressing T cells. These findings suggest TNF blockade therapy is of value for refractory NEMO colitis with gene reversion.


NEMO colitis infliximab gene reversion 



We profoundly thank for Dr. Kazuko Uno of the Louis-Pasteur Medical Research Center in Japan for support of our experiments and Dr. Maiko Kai and Dr. Naoki Karasawa1 for their warm care of patients. This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Conflict of Interests

The authors declare no competing financial interests.

Supplementary material

10875_2011_9600_MOESM1_ESM.pptx (297 kb)
Supplementary Fig. 1 Manifestations of our X-EDA-ID patient. (A) Herpes zoster was seen in his left chest. (B) Hypodontia and conical-shaped teeth at 4 years of age. (C) The radiograph of teeth was taken at 8 years (PPTX 296 kb)
10875_2011_9600_MOESM2_ESM.pptx (63 kb)
Supplementary Fig. 2 Frequency of TCR Vα and Vβ repertoires in our X-EDA-ID patient. Bar graphs indicate the semiquantitative assessment of TCR V gene usage in peripheral blood T cells (PPTX 63.3 kb)


  1. 1.
    Zonana J, Elder M, Schneider L, et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet. 2000;67:1555–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Döffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet. 2001;27:277–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Jain A, Ma CA, Liu S, et al. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol. 2001;2:223–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest. 2002;109:1501–9.PubMedGoogle Scholar
  5. 5.
    Orange JS, Jain A, Ballas ZK, et al. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol. 2004;113:725–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Pai S, Levy O, Jabara H, et al. Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency. J Allergy Clin Immunol. 2008;122:1113–1118.e1111.PubMedCrossRefGoogle Scholar
  7. 7.
    Tono C, Takahashi Y, Terui K, et al. Correction of immunodeficiency associated with NEMO mutation by umbilical cord blood transplantation using a reduced-intensity conditioning regimen. Bone Marrow Transplant. 2007;39:801–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Mancini AJ, Lawley LP, Uzel G. X-linked ectodermal dysplasia with immunodeficiency caused by NEMO mutation: early recognition and diagnosis. Arch Dermatol. 2008;144:342–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Fish J, Duerst R, Gelfand E, et al. Challenges in the use of allogeneic hematopoietic SCT for ectodermal dysplasia with immune deficiency. Bone Marrow Transplant. 2009;43:217–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Permaul P, Narla A, Hornick J, et al. Allogeneic hematopoietic stem cell transplantation for X-linked ectodermal dysplasia and immunodeficiency: case report and review of outcomes. Immunol Res. 2009;44:89–98.PubMedCrossRefGoogle Scholar
  11. 11.
    Cheng L, Kanwar B, Tcheurekdjian H, et al. Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol. 2009;132:124–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Hanson E, Monaco-Shawver L, Solt L, et al. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol. 2008;122:1169–1177.e1116.PubMedCrossRefGoogle Scholar
  13. 13.
    Takada H, Nomura A, Ishimura M, et al. NEMO mutation as a cause of familial occurrence of Behçet's disease in female patients. Clin Genet. 2010;78:575–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Marks DJ, Miyagi K, Rahman FZ, et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol. 2009;104:117–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Nagano M, Kimura N, Ishii E, et al. Clonal expansion of alphabeta-T lymphocytes with inverted Jbeta1 bias in familial hemophagocytic lymphohistiocytosis. Blood. 1999;94:2374–82.PubMedGoogle Scholar
  17. 17.
    Kimura N, Toyonaga B, Yoshikai Y, et al. Sequences and repertoire of the human T cell receptor alpha and beta chain variable region genes in thymocytes. Eur J Immunol. 1987;17:375–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Nishikomori R, Akutagawa H, Maruyama K, et al. X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival. Blood. 2004;103:4565–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Ogura Y, Imamura Y, Murakami Y, et al. Intracellular cytokine patterns of peripheral blood T cells as a useful indicator of activeness of Crohn's disease. Hiroshima J Med Sci. 2005;54:1–8.PubMedGoogle Scholar
  20. 20.
    Stephan V, Wahn V, Le Deist F, et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 1996;335:1563–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Wada T, Yasui M, Toma T, et al. Detection of T lymphocytes with a second-site mutation in skin lesions of atypical X-linked severe combined immunodeficiency mimicking Omenn syndrome. Blood. 2008;112:1872–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Hirschhorn R, Yang D, Puck J, et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet. 1996;13:290–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Wada T, Toma T, Okamoto H, et al. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency. Blood. 2005;106:2099–101.PubMedCrossRefGoogle Scholar
  24. 24.
    Ariga T, Kondoh T, Yamaguchi K, et al. Spontaneous in vivo reversion of an inherited mutation in the Wiskott–Aldrich syndrome. J Immunol. 2001;166:5245–9.PubMedGoogle Scholar
  25. 25.
    Filipe-Santos O, Bustamante J, Haverkamp MH, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med. 2006;203:1745–59.PubMedCrossRefGoogle Scholar
  26. 26.
    Nenci A, Huth M, Funteh A, et al. Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling. Hum Mol Genet. 2006;15:531–42.PubMedCrossRefGoogle Scholar
  27. 27.
    Van den Brande J, Braat H, van den Brink G, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774–85.PubMedCrossRefGoogle Scholar
  28. 28.
    Nos P, Bastida G, Beltran B, et al. Crohn's disease in common variable immunodeficiency: treatment with antitumor necrosis factor alpha. Am J Gastroenterol. 2006;101:2165–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Chua I, Standish R, Lear S, et al. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 2007;150:306–11.PubMedCrossRefGoogle Scholar
  30. 30.
    Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51:1429–34.PubMedCrossRefGoogle Scholar
  31. 31.
    Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62:2517–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Tomoyuki Mizukami
    • 1
    • 2
  • Megumi Obara
    • 1
  • Ryuta Nishikomori
    • 3
  • Tomoki Kawai
    • 3
  • Yoshihiro Tahara
    • 4
  • Naoki Sameshima
    • 5
  • Kousuke Marutsuka
    • 5
  • Hiroshi Nakase
    • 6
  • Nobuhiro Kimura
    • 7
  • Toshio Heike
    • 3
  • Hiroyuki Nunoi
    • 1
    Email author
  1. 1.Division of Pediatrics, Department of Reproductive and Developmental Medicine, Faculty of MedicineUniversity of MiyazakiMiyazakiJapan
  2. 2.Kumamoto Saishunso National HospitalKumamotoJapan
  3. 3.Department of PediatricsKyoto University Graduate School of MedicineKyotoJapan
  4. 4.Department of Gastroenterology and Hematology, Faculty of MedicineUniversity of MiyazakiMiyazakiJapan
  5. 5.Department of Pathophysiology, Faculty of MedicineUniversity of MiyazakiMiyazakiJapan
  6. 6.Department of Gastroenterology and HepatologyKyoto University Graduate School of MedicineKyotoJapan
  7. 7.Division of Medical Oncology, Hematology and Infectious Disease, Department of MedicineFukuoka UniversityFukuokaJapan

Personalised recommendations